These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11311196)

  • 1. The effect of low-dose interleukin-2-based immunotherapy on salivary function and composition in patients with metastatic renal cell carcinoma.
    Nagler RM; Gez E; Rubinov R; Laufer D; Ben-Aryeh H; Gaitini D; Filatov M; Kuten A
    Arch Oral Biol; 2001 Jun; 46(6):487-93. PubMed ID: 11311196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
    Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of pilocarpine on salivary constituents in patients with chronic graft-versus-host disease.
    Nagler RM; Nagler A
    Arch Oral Biol; 2001 Aug; 46(8):689-95. PubMed ID: 11389860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral changes in interleukin-2 treated patients: a preliminary report.
    Marmary Y; Shiloni E; Katz J
    J Oral Pathol Med; 1992 May; 21(5):230-1. PubMed ID: 1403839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
    J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo regulation of transforming growth factor beta 1 transcription by immunotherapy: interleukin-2 impairs interferon-alpha-stimulated increase in steady-state mRNA levels of transforming growth factor beta 1.
    Jahn B; Brieger J; Fenchel K; Mitrou PS; Bergmann L
    Cancer Immunol Immunother; 1994 May; 38(5):304-10. PubMed ID: 8162612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematotoxicity of interleukin-2 in man: clinical effects and comparison of various treatment regimens.
    Schomburg A; Kirchner H; Atzpodien J
    Acta Haematol; 1993; 89(3):119-31. PubMed ID: 8362600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
    Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
    Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European studies of interleukin-2 in metastatic renal cell carcinoma.
    Atzpodien J; Kirchner H; Hänninen EL; Körfer A; Fenner M; Menzel T; Deckert M; Franzke A; Jonas U; Poliwoda H
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):22-6. PubMed ID: 8284688
    [No Abstract]   [Full Text] [Related]  

  • 12. Major salivary gland dysfunction in patients with hematological malignancies receiving interleukin-2-based immunotherapy post-autologous blood stem cell transplantation (ABSCT).
    Nagler A; Nagler R; Ackerstein A; Levi S; Marmary Y
    Bone Marrow Transplant; 1997 Oct; 20(7):575-80. PubMed ID: 9337059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo time and dose dependency of interleukin-6 secretion in response to low-dose subcutaneous recombinant interleukin-2.
    Meffert M; Hanninen EL; Menzel T; Schomburg A; Duensing S; Dallmann I; Grosse J; Vocke S; Buer J; Deckert M
    Cancer Biother; 1994; 9(4):307-16. PubMed ID: 7719378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sialometrical and sialochemical analysis of patients with chronic graft-versus-host disease--a prolonged study.
    Nagler RM; Nagler A
    Cancer Invest; 2003; 21(1):34-40. PubMed ID: 12643007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.
    Bukowski RM
    Cancer; 1997 Oct; 80(7):1198-220. PubMed ID: 9317170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole saliva in systemic lupus erythematosus patients.
    Ben-Aryeh H; Gordon N; Szargel R; Toubi E; Laufer D
    Oral Surg Oral Med Oral Pathol; 1993 Jun; 75(6):696-9. PubMed ID: 7685874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulated whole salivary flow rate and composition in menopausal women with oral dryness feeling.
    Agha-Hosseini F; Mirzaii-Dizgah I; Moghaddam PP; Akrad ZT
    Oral Dis; 2007 May; 13(3):320-3. PubMed ID: 17448216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of very low doses of immunotherapy in advanced renal cell cancer.
    Buzio C; De Palma G; Passalacqua R; Potenzoni D; Ferrozzi F; Cattabiani MA; Manenti L; Borghetti A
    Br J Cancer; 1997; 76(4):541-4. PubMed ID: 9275034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
    Atzpodien J; Kirchner H; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.